Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neo-TIME: Neoadjuvant Tislelizumab + Chemo in OSCC
NCT05862168Phase 2Recruiting
- Start
- May 2023
- Primary completion
- Jun 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tislelizumab in oral squamous cell carcinoma (OSCC). Started May 2023; status: recruiting.
02
Drugs
tislelizumab
03
Conditions
oral squamous cell carcinoma (OSCC)
Beyond the preview
Go deeper on NCT05862168.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05862168.